Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212716 | 0.90 | HTR6 (0.66) | HTR6HTR2B | |
| SCHEMBL4201696 | 0.87 | HTR6 (0.69) | HTR6HTR2B | |
| SCHEMBL3320144 | 0.86 | HTR6 (0.53) | HTR6KMT2APKM | |
| Hydrochloric Acid SCHEMBL4204164 | 0.86 | HTR6 (0.68) | HTR6HTR2B | |
| SCHEMBL4214353 | 0.85 | HTR6 (0.68) | HTR6 | |
| SCHEMBL4206341 | 0.85 | HTR6 (0.67) | HTR6 | |
| SCHEMBL4209627 | 0.84 | HTR6 (0.68) | HTR6HTR2BAKR1B1LMNAHTT | |
| SCHEMBL4211456 | 0.84 | HTR6 (0.68) | HTR6 | |
| SCHEMBL4217325 | 0.84 | HTR6 (0.51) | HTR6MEN1MAPTKMT2ATSHR | |
| SCHEMBL30909133 | 0.83 | DYRK1A (0.48) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482461-B2 | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-01-27 | — | — | US | claimed |
| EP-2001865-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007117413-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070238724-A1 | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-11 | — | — | US | claimed |
| US-20090105303-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-04-23 | — | — | US | disclosed |
| US-7482461-B2 | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-01-27 | — | — | US | disclosed |
| EP-2001865-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117413-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238724-A1 | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238724-A1 | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR2C, HTR3B | HTR6 1/4885HTR2B 13/4885AKR1B1 2298/4885 |
| US-20090105303-A1 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | HTR6 1/4885HTR2B 13/4885AKR1B1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.